Evotec Earns Bayer Milestone Under Multi-Target Alliance

Evotec’s multi-target collaboration with Bayer HealthCare has reached an important milestone, transitioning an undisclosed molecule into preclinical development for the treatment of endometriosis. Financial details were not disclosed.
 
Under the October 2012 agreement, the companies aim to develop three clinical candidates within a five-year term. Both parties contribute drug targets and technology infrastructures and share the responsibility for early research and preclinical characterization of potential candidates to treat endometriosis.
 
Dr. Mario Polywka, chief operating officer of Evotec, said, “We are very pleased to achieve this validation of our joint work with the Bayer team. Both teams of scientists have developed a tremendous relationship and collaborative way of working and we look forward to continue this productive work and focus our efforts on bringing forward new drug candidates to tackle this significant disease.”